Page 172 - NobleCon19revC2_Neat

Health Care
Date November 21, 2023 Health Care
52wk High $2.87
52wk Low $0.40 Unicycive Therapeutics, Inc. UNCY $0.50
4300 El Camino Real
Los Altos, CA 94022

(USD - in millions) unicycive.com
Market Cap 18.1
Enterprise 4.6
Basic Shares Out. 34.75 COMPANY OVERVIEW
Float 18.00
Institutional Holdings 10.14% Detailed Analysis:Channelchek.com
Short Interest 0.06
Avg. 90-Day Volume 0.05 Unicycive Therapeutics Inc is a biotechnology company dedicated to
developing treatments for certain medical conditions. It is focusing on
kidney diseases. The company’s lead drug, Renazorb, is a novel
phosphate-binding agent being developed for the treatment of
EPS Data hyperphosphatemia. Unicycive’s other drug, UNI-494, is a new
chemical entity with the issued composition of matter patent protection
2021 2022 2023 in late preclinical development for the treatment of acute kidney injury.
CQ1 N/A (0.24) (0.97)
CQ2 (0.13) (0.24) (0.29)

CQ3 (0.37) (0.37) (0.13)
CQ4 (0.17) (0.35) (0.18)
CY (0.86) (1.20) (1.24) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) 0.10
ROE (ttm) -696.63
Debt-to-Total Cap. (mrq) 20.14
Fiscal Year End 31-Dec
4300 El Camin Los Altos CA 94022

Key Executives
CEO: Gupta, Shalabh
CFO: Townsend, John
COO: N/A
IR: N/A
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert LeBoyer MEMBERS: FINRA, SIPC, MSRB
Following the conference, complete video library of presentations will be
rleboyer@noblelsp.com available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures